A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | July 2012 |
| End Date: | December 2012 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Phase 1, Open-label, Single-dose, Randomized, 4-treatment, 4- Period, Crossover, Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene (Bza) Compared With A Reference Tablet Formulation of Bza/Conjugated Estrogens (ce) in Healthy Postmenopausal Women
The purpose of this study is to evaluate 3 test formulations relative to a reference
formulation.
Inclusion Criteria:
- Generally healthy postmenopausal women
- Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight >= 50 kg
Exclusion Criteria:
- Pregnant or nursing females; females of childbearing potential
We found this trial at
1
site
Click here to add this to my saved trials
